Andy Chen

803 total citations
20 papers, 269 citations indexed

About

Andy Chen is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Andy Chen has authored 20 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 3 papers in Genetics. Recurrent topics in Andy Chen's work include CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Viral-associated cancers and disorders (3 papers). Andy Chen is often cited by papers focused on CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Viral-associated cancers and disorders (3 papers). Andy Chen collaborates with scholars based in United States, Italy and Poland. Andy Chen's co-authors include Surai Jones, Mark W. Brunvand, Richard T. Maziarz, Levanto Schachter, Sarah Nagle, Eneida R. Nemecek, Philipp W. Raess, Craig Okada, Brandon Hayes‐Lattin and Joseph P. McGuirk and has published in prestigious journals such as Blood, Clinical Cancer Research and British Journal of Haematology.

In The Last Decade

Andy Chen

19 papers receiving 262 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andy Chen United States	9	206	114	60	40	36	20	269
Timothy Voorhees United States	8	152 0.7×	80 0.7×	53 0.9×	55 1.4×	20 0.6×	37	240
Elizabeth Budde United States	9	161 0.8×	63 0.6×	105 1.8×	48 1.2×	38 1.1×	26	275
J. Kaitlin Morrison United States	8	230 1.1×	254 2.2×	100 1.7×	37 0.9×	134 3.7×	17	380
Yngvild Nuvin Blaker Norway	7	204 1.0×	173 1.5×	32 0.5×	101 2.5×	50 1.4×	12	296
Marie-Elisabeth Goebeler Germany	6	324 1.6×	197 1.7×	40 0.7×	110 2.8×	67 1.9×	7	392
Keith Fay Australia	4	230 1.1×	162 1.4×	33 0.6×	70 1.8×	40 1.1×	7	277
Huang Huang Canada	8	343 1.7×	245 2.1×	42 0.7×	93 2.3×	69 1.9×	14	413
Nicole Adrian Germany	8	323 1.6×	192 1.7×	85 1.4×	131 3.3×	66 1.8×	10	428
Nathan Denlinger United States	10	213 1.0×	55 0.5×	76 1.3×	111 2.8×	26 0.7×	31	336
Sylvia Snauwaert Belgium	10	182 0.9×	129 1.1×	85 1.4×	108 2.7×	55 1.5×	34	324

Countries citing papers authored by Andy Chen

Since Specialization

Citations

This map shows the geographic impact of Andy Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Chen more than expected).

Fields of papers citing papers by Andy Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Chen. The network helps show where Andy Chen may publish in the future.

Co-authorship network of co-authors of Andy Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Chen. A scholar is included among the top collaborators of Andy Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Chen. Andy Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rojek, Alexandra E., Nausheen Ahmed, Sairah Ahmed, et al.. (2024). CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. Blood. 144(Supplement 1). 4503–4503.

Williamson, Staci, Levanto Schachter, Andy Chen, et al.. (2024). Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(2). e120–e125. 4 indexed citations

Riedell, Peter A., Loretta J. Nastoupil, Alejandro Luna, et al.. (2023). Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. Blood. 142(Supplement 1). 617–617. 7 indexed citations

Lutfi, Forat, David L. Porter, Veronika Bachanová, et al.. (2023). “Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”. Blood. 142(Supplement 1). 4887–4887. 1 indexed citations

Mehta, Amitkumar, Umar Farooq, Andy Chen, et al.. (2022). Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. Blood. 140(Supplement 1). 4577–4578. 34 indexed citations

Bhaskar, Shakthi, Stephen J. Schuster, Loretta J. Nastoupil, et al.. (2022). Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma. Blood. 140(Supplement 1). 366–368. 1 indexed citations

Fowler, Nathan, Michael Dickinson, Monalisa Ghosh, et al.. (2021). Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study. Blood. 138(Supplement 1). 3533–3533. 4 indexed citations

Williamson, Staci, Rebecca Silbermann, Eva Medvedova, et al.. (2021). Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience. Clinical Lymphoma Myeloma & Leukemia. 22(2). 105–112. 1 indexed citations

Nagle, Sarah, Philipp W. Raess, Levanto Schachter, et al.. (2021). Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. American Journal of Hematology. 96(4). 455–461. 44 indexed citations

10.

Park, Jae H., Nitin Jain, Andy Chen, et al.. (2020). A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies. Blood. 136(Supplement 1). 15–16. 9 indexed citations

11.

Chen, Andy, et al.. (2018). Colorectal Lymphoma: A Review. Clinics in Colon and Rectal Surgery. 31(5). 309–316. 17 indexed citations

12.

Advani, Ranjana H., Daniel Lebovic, Andy Chen, et al.. (2016). Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 23(5). 1167–1176. 65 indexed citations

13.

Chen, Robert, Nancy L. Bartlett, Pauline Brice, et al.. (2016). Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. OncoTargets and Therapy. 9. 2027–2027. 1 indexed citations

14.

Phillips, Tycel, Mark W. Brunvand, Andy Chen, et al.. (2016). Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. Blood. 128(22). 622–622. 27 indexed citations

15.

Chen, Andy, et al.. (2016). Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells. Blood. 128(22). 289–289. 8 indexed citations

16.

Ramsey, Scott D., Auayporn Nademanee, Tamás Masszi, et al.. (2016). Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. British Journal of Haematology. 175(5). 860–867. 21 indexed citations

17.

Moskowitz, Craig H., Tamás Masszi, Edward Agura, et al.. (2014). The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 20(2). S115–S116. 4 indexed citations

18.

Horwitz, Sarah McCue, Julie M. Vose, Ranjana H. Advani, et al.. (2009). Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.. Blood. 114(22). 1674–1674. 11 indexed citations

19.

Horwitz, Sarah McCue, Julie M. Vose, Ranjana H. Advani, et al.. (2008). A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies.. Blood. 112(11). 1570–1570. 5 indexed citations

20.

Valcour, André, et al.. (2006). Correlation of the turbo-MP RIA with ImmunoCAP FEIA for determination of food allergen-specific immunoglobulin E.. PubMed. 36(1). 79–87. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact